Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of Dickkopf-1 protein in preparation of medicament for treating X-linked hypophosphatemia rickets

A technology for hypophosphatemia and rickets, applied in the field of biomedicine, can solve problems such as no clinical treatment methods, and achieve the effect of treating X-linked hypophosphatemia rickets

Pending Publication Date: 2019-11-01
ANGITIA BIOPHARMACEUTICALS GUANGZHOU LTD
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is currently no effective clinical treatment for X-linked hypophosphatemic rickets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Dickkopf-1 protein in preparation of medicament for treating X-linked hypophosphatemia rickets
  • Application of Dickkopf-1 protein in preparation of medicament for treating X-linked hypophosphatemia rickets
  • Application of Dickkopf-1 protein in preparation of medicament for treating X-linked hypophosphatemia rickets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Mouse Osteoblast (MC3T3-E1) Cell Culture and Measurement of Extracellular Collagen Deposition

[0019] Experimental method: Mouse osteoblasts (MC3T3-E1) were obtained from Yuchun Biotechnology Co., Ltd. (Yuchun Biology, Shanghai), cultured in α-basic medium (α-MEM), supplemented with 10% fetal bovine serum and 1 % penicillin, streptomycin, cultured in 5% carbon dioxide, 95% oxygen, and 37°C, and replaced with fresh culture medium every 3-5 days to keep the culture medium in a subsaturated state. In preparation for the mineralization experiment, count the cells with a cell counter, then add 20,000 cells to each well of a 24-well culture plate and culture to 80% saturation. Then add 5mMβ-glycerophosphate and 100μg / ml ascorbic acid (called mineralization medium) to the medium, and change the medium every 3 days. In order to prove that the cells have the ability to secrete extracellular matrix mineralization, the cells cultured in the normal medium (normal medium) and the ...

Embodiment 2

[0022] Experimental method: Dkk1 protein was purchased from R&D Biosystems, USA. The cells cultured in Example 1 were divided into four groups: the first group was normal medium cultured cells without adding any reagents; the second group was mineralization medium control, added 0.2 μg / ml, 0.4 μg / ml and 0.8 Normal saline at the dose of μg / ml; the third group was the first day of the experiment, and 0.2 μg / ml, 0.4 μg / ml and 0.8 μg / ml of Dkk1 were added to the mineralization medium; the fourth group was the tenth day of the experiment Day, 0.2 μg / ml, 0.4 μg / ml and 0.8 μg / ml doses of Dkk1 were added to the mineralization medium. On the fourteenth day of the experiment, the medium for the experiment was collected, and the cultured cells were also collected in TRIzol reagent for future use. ELISA kits were used to detect the levels of mouse P1NP (procollagen I-type n-terminal propeptide, Elabscience, China) and mouse OCN (osteocalcin, Elabscience, China), and the experimental resu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of Dickkopf-1 (Dkk1) protein in preparation of a medicament for treating X-linked hypophosphatemia rickets, and belongs to the technical field of biological medicines. The invention provides the application of the Dkk1 protein in preparation of the medicament for treating X-linked hypophosphatemia rickets, and the Dkk1 protein is used for regulating and controlling the osteocalcin level and the bone turnover marker P1NP level, and achieves the effect of treating X-linked hypophosphatemia rickets.

Description

technical field [0001] The invention relates to the use of Dickkopf-1 (Dkk1) protein in preparing a medicament for treating X-linked hypophosphatemia rickets, belonging to the technical field of biomedicine. Background technique [0002] X-linked hypophosphatemic rickets (XLH) (OMIM 307800) is a rare orthopedic genetic disorder characterized by low levels of phosphate in the blood due to abnormal functioning of the kidneys in processing phosphate, resulting in loss of phosphate into the urine (phosphate wasting) and cause soft, weak bones (Rickets, rickets or rickets). X-linked hypophosphatemic rickets is caused by mutations in the PHEX (X-linked carbonate regulatory gene) gene, which encodes an endopeptidase that is mainly expressed in osteoblasts, bone cells, odontoblasts, and cementum plasmoblast surface. XLH follows the X-linked transmission mode with dominant expression, and causes not only orthopedic abnormalities, but also hypophosphatemia. Patients present with hem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P19/08
CPCA61K38/1709A61P19/08
Inventor 袁葆直柯华珠刘坤锋李丹梁文博
Owner ANGITIA BIOPHARMACEUTICALS GUANGZHOU LTD